Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase I trial to look at safety and how a patient's body will tolerate the treatment at different dosages.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gilead Sciences; Immunomedics, Inc.
• Treatments: Antibodies; Veltuzumab

Criteria

Inclusion Criteria:

• CD20+ B-cell non-Hodgkin's lymphoma (NHL) with measurable disease